Table 3.

Comparisons of Quality-of-Life Scores at Baseline and Follow-Up According to Treatment Status

	Baseline	3 Months	6 Months	12 Months	Time	Group	Time × Group
Parameter	Mean ± Standard Error				P-Value
Men
BDI
Placebo	2.9 ± 0.4	2.0 ± 0.4	1.9 ± 0.4	2.8 ± 0.5	<.001	.26	.85
DHEA	3.4 ± 0.4	2.7 ± 0.4	2.6 ± 0.4	3.2 ± 0.5
SF-36 Physical
Placebo	82.4 ± 1.7	82.9 ± 1.7	82.2 ± 1.7	83.2 ± 1.7	.86	.46	.61
DHEA	82.6 ± 1.7	80.8 ± 1.7	80.8 ± 1.7	80.7 ± 1.7
SF-36 Mental
Placebo	87.1 ± 1.3	86.6 ± 1.3	87.3 ± 1.4	87.6 ± 1.4	.72	.28	.92
DHEA	86.3 ± 1.3	85.1 ± 1.3	85.2 ± 1.4	85.3 ± 1.4
Life Satisfaction Index-Z
Placebo	22.6 ± 0.5	23.1 ± 0.5	23.4 ± 0.5	23.2 ± 0.5	.48	.06	.66
DHEA	21.9 ± 0.5	21.8 ± 0.5	22.1 ± 0.5	22.2 ± 0.5
Satisfaction with Life Scale
Placebo	28.2 ± 0.7	27.1 ± 0.7	27.7 ± 0.8	27.5 ± 0.8	.06	.22	.94
DHEA	27.3 ± 0.7	25.9 ± 0.7	27.1 ± 0.7	26.5 ± 0.7
International Index of Erectile Function
Placebo	46.3 ± 2.9	48.4 ± 2.9	44.5 ± 2.9	46.5 ± 3.0	.09	.45	.86
DHEA	43.4 ± 2.9	45.3 ± 2.9	43.2 ± 2.9	43.3 ± 2.9
Women
BDI
Placebo	4.3 ± 0.6	3.8 ± 0.6	3.6 ± 0.6	3.5 ± 0.6	.02	.50	.58
DHEA	5.3 ± 0.6	4.1 ± 0.6	3.9 ± 0.6	4.0 ± 0.6
SF-36 Physical
Placebo	76.8 ± 2.1	76.1 ± 2.1	75.4 ± 2.1	78.0 ± 2.1	.07	.81	.66
DHEA	78.9 ± 2.0	75.3 ± 2.1	75.9 ± 2.1	78.5 ± 2.1
SF-36 Mental
Placebo	82.8 ± 1.7	82.7 ± 1.7	83.4 ± 1.7	83.5 ± 1.7	.08	.62	.25
DHEA	82.1 ± 1.7	80.0 ± 1.7	83.8 ± 1.7	82.4 ± 1.7
Life Satisfaction Index-Z
Placebo	21.6 ± 0.6	21.5 ± 0.6	21.7 ± 0.6	22.1 ± 0.6	.43	.60	.80
DHEA	21.0 ± 0.6	21.4 ± 0.6	21.3 ± 0.6	21.6 ± 0.6
Satisfaction with Life Scale
Placebo	26.8 ± 0.8	24.5 ± 0.8	26.7 ± 0.8	27.5 ± 0.9	.004	.68	.15
DHEA	26.0 ± 0.8	25.6 ± 0.8	26.3 ± 0.9	26.1 ± 0.9
Female Sexual Function Index
Placebo	16.4 ± 1.6	16.8 ± 1.6	16.4 ± 1.6	16.4 ± 1.6	.29	.51	.19
DHEA	13.3 ± 1.6	14.7 ± 1.6	17.2 ± 1.7	15.4 ± 1.7

BDI = Beck Depression Inventory; DHEA = dehydroepiandrosterone; SF-36 = Medical Outcomes Study 36-item Short Form Survey.